Skip to main content
SpringerLink
Log in

Biologicals beim Ovarialkarzinom

Stand der Entwicklung

Biological therapy in ovarian cancer

State of the art

  • Gynäkologie aktuell
  • Published:
Der Gynäkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Krebsregister des Robert-Koch Instituts. http://www.krebsdaten.de

  2. Bois A du, Reuss A, Pujade-Lauraine E et al (2009) The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 15:1234–1244

    Article  Google Scholar 

  3. Aletti GD, Dowdy SC, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100(2):283–287

    Article  PubMed  Google Scholar 

  4. Bois A du, Lück HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329

    Article  PubMed  Google Scholar 

  5. Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338. doi:10.1016/S0140-6736(09)61157-0

    Article  PubMed  CAS  Google Scholar 

  6. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579–591. doi:10.1038/nrc2403

    Article  PubMed  CAS  Google Scholar 

  7. Hefler LA, Mustea A, Könsgen D et al (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13(3):898–901

    Article  PubMed  CAS  Google Scholar 

  8. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496. doi:10.1056/NEJMoa1103799

    Article  PubMed  CAS  Google Scholar 

  9. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483. doi:10.1056/NEJMoa1104390

    Article  PubMed  CAS  Google Scholar 

  10. Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045. doi:10.1200/JCO.2012.42.0505

    Article  PubMed  CAS  Google Scholar 

  11. Pujade-Lauraine E, Hilpert F, Weber B et al (2012) AURELIA: a randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. ASCO (Abstract 5002)

  12. Gotlieb WH, Amant F, Advani S et al (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13(2):154–162. doi:10.1016/S1470-2045(11)70338-2

    Article  PubMed  CAS  Google Scholar 

  13. Matei D, Sill MW, Lankes HA et al (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29(1):69–75. doi:10.1200/JCO.2009.26.7856

    Article  PubMed  Google Scholar 

  14. Baumann KH, Bois A du, Meier W et al (2012) A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 23(9):2265–2271. doi:10.1093/annonc/mds003

    Article  PubMed  CAS  Google Scholar 

  15. Friedlander M, Hancock KC, Rischin D et al (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119(1):32–37. doi:10.1016/j.ygyno.2010.05.033

    Article  PubMed  CAS  Google Scholar 

  16. Ledermann JA, Hackshaw A, Kaye S et al (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29(28):3798–3804. doi:10.1200/JCO.2010.33.5208

    Article  PubMed  CAS  Google Scholar 

  17. Karlan BY, Oza AM, Richardson GE et al (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362–371. doi:10.1200/JCO.2010.34.3178

    Article  PubMed  CAS  Google Scholar 

  18. Bell-McGuinn KM, Matthews CM, Ho SN et al (2011) A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121(2):273–279. doi:10.1016/j.ygyno.2010.12.362

    Article  PubMed  CAS  Google Scholar 

  19. Schilder RJ, Sill MW, Lee RB et al (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 26(20):3418–3425. doi:10.1200/JCO.2007.14.3420

    Article  PubMed  CAS  Google Scholar 

  20. Matei D, Emerson RE, Schilder J et al (2008) Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113(4):723–732. doi:10.1002/cncr.23605

    Article  PubMed  CAS  Google Scholar 

  21. Noguera IR, Sun CC, Broaddus RR et al (2012) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125(3):640–645. doi:10.1016/j.ygyno.2012.02.034

    Article  PubMed  CAS  Google Scholar 

  22. Ramasubbaiah R, Perkins SM, Schilder J et al (2011) Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 123(3):499–504. doi:10.1016/j.ygyno.2011.08.033

    Article  PubMed  CAS  Google Scholar 

  23. Matei D, Sill MW, Lankes HA et al (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29(1):69–75. doi:10.1200/JCO.2009.26.7856

    Article  PubMed  Google Scholar 

  24. Raja FA, Griffin CL, Qian W et al (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 105(7):884–889. doi:10.1038/bjc.2011.334

    Article  PubMed  CAS  Google Scholar 

  25. Matulonis UA, Berlin S, Ivy P et al (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27(33):5601–5606. doi:10.1200/JCO.2009.23.2777

    Article  PubMed  CAS  Google Scholar 

  26. Annunziata CM, Walker AJ, Minasian L et al (2010) Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16(2):664–672. doi:10.1158/1078-0432.CCR-09-2308

    Article  PubMed  CAS  Google Scholar 

  27. O’Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205–214. doi:10.1056/NEJMoa1011418

    Article  Google Scholar 

  28. O’Shaughnessy J et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine-carboplatin (GC) in metastatic triple-negative breast cancer (TNBC). ASCO (Abstract 1007)

  29. Rigakos G, Razis E (2012) BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 17(7):956–962. doi:10.1634/theoncologist.2012-0028

    Article  PubMed  Google Scholar 

  30. Oza AM, Cibula D, Benzaquen AO et al (2012) Olaparib plus paclitaxel and carboplatin followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label Phase II study. ASCO (Abstract 5001)

  31. Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382–1392. doi:10.1056/NEJMoa1105535

    Article  PubMed  CAS  Google Scholar 

  32. Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27(16):2705–2711. doi:10.1200/JCO.2008.19.7681

    Article  PubMed  CAS  Google Scholar 

  33. Reinartz S, Köhler S, Schlebusch H et al (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10(5):1580–1587

    Article  PubMed  CAS  Google Scholar 

  34. Pfisterer J, Berek JS, Casado A et al (2011) ASCO (Abstract 5002)

  35. Berek J, Taylor P, McGuire W et al (2009) Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27(3):418–425. doi:10.1200/JCO.2008.17.8400

    Article  PubMed  CAS  Google Scholar 

  36. Fu S, Hennessy BT, Ng CS et al (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47–53. doi:10.1016/j.ygyno.2012.04.006

    Article  PubMed  CAS  Google Scholar 

  37. Konner JA, Bell-McGuinn KM, Sabbatini P et al (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16(21):5288–5295. doi:10.1158/1078-0432.CCR-10-0700

    Article  PubMed  CAS  Google Scholar 

  38. Naumann RW, Coleman RL, Burger RA et al (2011) PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. ASCO (Abstract 5045)

  39. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. doi:10.1056/NEJMoa1109653

    Article  PubMed  CAS  Google Scholar 

  40. Behbakht K, Sill MW, Darcy KM et al (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123(1):19–26. doi:10.1016/j.ygyno.2011.06.022

    Article  PubMed  CAS  Google Scholar 

  41. Fu S, Hennessy BT, Ng CS et al (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47–53. doi:10.1016/j.ygyno.2012.04.006

    Article  PubMed  CAS  Google Scholar 

  42. Burges A, Wimberger P, Kümper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13):3899–3905

    Article  PubMed  CAS  Google Scholar 

  43. Schilder RJ, Brady WE, Lankes HA et al (2012) Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(1):70–74. doi:10.1016/j.ygyno.2012.06.009

    Article  PubMed  CAS  Google Scholar 

  44. Meier W, Bois A du, Rau J et al (2012) Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol 126(2):236–240. doi:10.1016/j.ygyno.2012.04.050

    Article  PubMed  CAS  Google Scholar 

  45. Matulonis UA, Sharma S, Ghamande S et al (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127(1):63–69. doi:10.1016/j.ygyno.2012.06.040

    Article  PubMed  CAS  Google Scholar 

  46. Matulonis UA, Lee J, Lasonde B et al (2013) ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 49(1):121–131. doi:10.1016/j.ejca.2012.07.020

    Article  PubMed  CAS  Google Scholar 

  47. Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28(7):1215–1223. doi:10.1200/JCO.2009.22.3354

    Article  PubMed  CAS  Google Scholar 

  48. Farley J, Brady WE, Vathipadiekal V et al (2013) Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14(2):134–140. doi:10.1016/S1470-2045(12)70572-7

    Article  PubMed  CAS  Google Scholar 

  49. Du Bois A, Floquet A, Kim et al. (2013) Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 31 (suppl; abstr LBA5503)

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. Keine Angaben

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Ulm, Prittwitzstr. 43, 89075, Ulm, Deutschland

    N. de Gregorio, F. Ebner, W. Janni &  A. Wöckel

Authors
  1. N. de Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ebner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Wöckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Wöckel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Gregorio, N., Ebner, F., Janni, W. et al. Biologicals beim Ovarialkarzinom. Gynäkologe 46, 666–671 (2013). https://doi.org/10.1007/s00129-013-3212-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-013-3212-0

Search

Navigation